Aclaris Announces Pricing of Public Offering of Common Stock
20 janv. 2021 08h45 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Announces Proposed Public Offering of Common Stock
19 janv. 2021 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
19 janv. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
Durable Clinical Activity over 12 Weeks was DemonstratedData Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid ArthritisATI-450, an...
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
15 déc. 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
New Scientific Advisory Board of Immuno-Inflammatory ExpertsPreliminary Topline Data for the ATI-450-RA-201 Trial Expected in January 2021 WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris...
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
16 nov. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
04 nov. 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisInitiated Phase 2a Trial of ATI-450, an...
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
20 oct. 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Present at Upcoming Investor Conferences
01 sept. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
07 août 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
•First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis •First Subject Dosed in Phase 2a Trial...
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
07 juil. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for...